Tag: pharma
Over 80 firms are involved in providing antibody drug discovery-related services; whereas close to 125 players are offering antibody discovery platforms
According to experts in this field, the industry is investigating antibodies against novel targets which are expected to drive the market in the coming years.
The antibody discovery services market is estimated to be worth around USD 6.5 billion by 2030 instead the antibody discovery platforms market is anticipated to be worth close to USD 6 billion by 2030, predicts Roots Analysis
Antibody therapeutics have made it possible to address the hard to target hotspots, rendering the domain of antibody discovery an emerging sector in the pharmaceutical industry
Growing at an annualized rate of over 9%, the antibody discovery services market is projected to be worth USD 6.5 billion by 2030; the antibody discovery platforms market is estimated to be worth close to USD 6 billion by 203
High target specificity and favorable safety profiles offered by antibody based pharmacological interventions has created a high demand for such molecules.
The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’ report
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated.
The STING pathway targeting technologies market
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy.
Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems, claims Roots An
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%
Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.
The microbial contract biomanufacturing market
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated.
The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030” report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next d
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy.
The microbial contract biomanufacturing market - Roots Analysis
Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics.
Many small / macro molecule-based STING pathway modulators
In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community.
The STING pathway targeting technologies market is projected
Roots Analysis has done a detailed study on STING Pathway targeting therapeutics and Technologies, 2020-2030, covering key aspects of the industry and identifying future growth opportunities.
The antibody discovery services and platforms market is projected to grow at an annualized rate of ~10%, till 2030
Roots Analysis has done a detailed study on Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots Analysis
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies.
The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030
Report features an extensive study on the contract service providers within the biopharmaceutical industry.
